Please login to the form below

Not currently logged in
Email:
Password:

Incisive Health appoints new director

Jean-Louis Roux joins the firm from EURORDIS

Incisive_Health_Jean_Louis_RouxIncisive Health has appointed Jean-Louis Roux as its new director to support the consultancy’s international business.

Previously serving the European Organisation for Rare Diseases (Eurordis) as its public affairs director, Roux has experience in leading firm’s engagement with European and international policy-makers.

He said: “The international health community faces real challenges, with distracted decision makers increasingly turning inwards.

“Having observed Incisive Health’s first steps on the international stage, I am impressed by the way the team combines real expertise and creativity at a time when both are clearly needed.

“I can’t wait to play my part in the next stage of Incisive Health International.”

With over 12 years of healthcare public affairs experience, acquired in corporate, NGO and consultancy environments,

Prior to his time at EURORDIS, Roux has previously worked for Bristol-Myers Squibb (BMS) in its Global Policy Advocacy and Government Affairs group.

Mike Birtwistle, founding partner of Incisive Health, said: “The appointment of Jean-Louis marks the next stage in our international development.

“We envisage a series of international hires to further bolster our offer in the coming months.”

5th April 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics